SEC Comment Letter for Zosano Pharma Corp (CIK 0001587221) — Jul 9, 2021
Zosano Pharma Corp (CIK 0001587221)
Date: July 9, 2021 · CIK: 0001587221 · Accession: 0000000000-21-008518
AI Filing Summary & Sentiment
File numbers found in text: 333-257682
Letter
United States securities and exchange commission logo July 9, 2021 Steven Lo President and Chief Executive Officer Zosano Pharma Corporation 34790 Ardentech Court Fremont, California 94555 Re:Zosano Pharma Corporation Registration Statement on Form S-3 Filed July 2, 2021 File No. 333-257682 Dear Mr. Lo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kathleen M. Wells, Esq.
Show Raw Text
United States securities and exchange commission logo
July 9, 2021
Steven Lo
President and Chief Executive Officer
Zosano Pharma Corporation
34790 Ardentech Court
Fremont, California 94555
Re:Zosano Pharma Corporation
Registration Statement on Form S-3
Filed July 2, 2021
File No. 333-257682
Dear Mr. Lo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Kathleen M. Wells, Esq.